237 results about "Treatment blood" patented technology

The present invention relates to hexabasic amino amidate derivatives, their preparation process, medicines using them as active components and method for curing diseases of angiogenesis and high vascular osmolarity by using them, and also relates to the application of them as medicines.

The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

The invention relates to a medicament containing a standardized dry extract of horse chestnut seeds which is active against various types of edema and diseases of the venous circulatory system and to a process for manufacturing this medicament. The dry seed extract is processed to the form of pellets which can be coated to obtain sustained release of the agent. In this way satisfying therapeutical blood levels of the triterpene glycosides as agent are achieved. The finished medicament according to the invention can best be provided as hard gelatin capsule or matrix tablet containing the extract pellets.

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

The invention relates to a nanometer medicinal elution apparatus in microcellular structure for storing and releasing multiple medicines and a preparation method thereof. The multiple medicines in the invention are selected from medicine therapeutic agents, carrier therapeutic genes and bioactive substances, wherein one or two of the medicine therapeutic agents is/are taxol and/or probucol. The preparation method of the medicinal elution apparatus in the invention mainly comprises the followings: 1) nanometer holes are prepared on the surface of the apparatus body; 2) multiple medicines are coated in the nanometer holes and on the surface of the apparatus body. The apparatus body in the invention does not contain polymers, thereby reducing the risk of long-term thrombus possibly caused by polymers; the nanometer holes on the surface of the apparatus body do not have any influence for mechanical property of the body, thereby being capable of efficiently controlling the releasing rate of medicines and obviously reducing the restenosis rate after surgical operations. The invention can be applied to various medicinal elution implanting apparatuses, particularly having good effects for curing vascular lesion and preventing blood vessel restenosis in vascular stents.

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

The present teachings provide devices and methods of engaging, capturing, and retrieving emboli. Specifically, one aspect of the present teachings provide a device comprising a generally cylindrical stent body, and a distal net. The stent body is configured to engage and capture emboli, while the distal net is configured to restrict blood flow, and capture embolic debris. Certain embodiments of the present teachings also provides devices and methods of engaging clots while better assist aspiration. Another aspect of the present teachings provide methods of use thereof to percutaneously removeblood clots with minimum risks.

A surgical apparatus for treating a blood clot in a vessel of a patient having an elongated member having an outer wall, a first hole at a distal portion and a second hole spaced proximally from the first hole positioned in a side wall. A first lumen is provided within the elongated member for blood flow through the second hole, through the lumen and exiting the first hole to maintain blood flow during treatment of the blood clot. An energy emitter emits energy to the blood clot or hardenings and a connector connects the energy emitter to an external energy source, wherein blood flows into the second hole positioned proximal of the blood clot and exits the first hole distal of the blood clot during activation of the energy emitter. In some instances when the apparatus is introduced from a retrograde ‘upstream” approach blood may flow through the device in the opposite direction.

The invention relates to the field of traditional Chinese medicine, and discloses a repair traditional Chinese medicine used for treating blood cell infected by flaviviridae. The traditional Chinese medicine is prepared from: by weight, herba tubocapsici anomali 30g-80g, cymbopogon citratus 20g-50g, camellia flower 10g-30g, citrus aurantium flower 10g-30g, bitter gourd 20g-50g, mint 20g-50g, phellodendron amurense 10g-30g, cypress leaf 10g-30g, salix leaf 10g-30g, persimmon leaf 15g-35g, perilla nankinensis 10g-20g, radix sophorae flavescentis 30g-60g, eleusine indica 25g-80g, syzygium aromaticum 10g-30g, lonicera japonica 30g-80g, agastache rugosus 20g-50g, portulaca oleracea 10g-30g, glycyrrhiza 5g-15g, chrysanthemum 10g-35g, and foeniculum vulgare 10g-35g. The traditional Chinese medicine has cure effect of the diseases such as dengue, Zika virus, encephalitis, hepatitis and liver cancer infected by flaviviridae spreading, can treat and repair the blood cell from the source, has prophylaxis and treatment effect on flaviviridae diseases, is without any toxicity and side effects, and can improve the cure rate and cure efficiency of patients.

The present invention relates to an enhanced adhesive bandage sandwich (FIG. 1) for compressing blood vessels and a kit for assembling said bandage sandwich. Moreover, the invention relates to a bandage or kit for use as a medicament, particularly, for use in treating varicose veins. The invention also relates to the use of a bandage sandwich or kit for compressing veins or arteries and a method to produce said bandage sandwich. Furthermore, the invention relates to a bandage sandwich obtainable by the inventive method.

A Chinese medicine for treating vascular dementia is prepared from 11 Chinese-medicinal materials including fleabane, gynostemma pentaphyllum, gingko leaf, American ginseng, etc through drying, pulverizing, distilling, decocting and concentrating.

The invention discloses a new Chinese traditional medicine composition for eliminating blood toxicity and improving blood viscosity and a preparation method thereof. The medicine composition mainly comprises the following raw material drugs: radices puerarire, Alisma orientale, radices trichosanthis, Coptis root, cortex moutan radicis, Notopterygium incisium, gypsum, Anemarrhena asphodeloides, radices sophorae flavescentis, honeysuckle, isatidis root, Sophora subprostrata, fresh rehmannia root, radices paeoniae rubra, Magnolia officinalis, tuckahoe, plantago seed, Desmodium styracifolium, Polygonum cuspidatum, rhizoma cyperi, Curcuma aromatica, fructus aurantii immaturus, hawthorn and malt. The medicine composition can be prepared into a usual preparation for oral use according to the conventional method of Chinese medicine. The invention can obviously eliminate blood toxicity and improve blood viscosity with exact curative effect and quick effect for a long time; moreover, the invention has the advantages of little toxic and side effect, low cost, and the like.

A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.

The invention relates to the providing of hydrophobic and hydrophilic polymer-based hollow fiber membranes containing a water-insoluble antioxidant; in particular, the invention relates to the providing of hollow fiber membranes for the extracorporeal treatment of blood, wherein the hollow fiber membranes have improved biocompatibility relative to treatment blood, in particular improved complement activation and lower platelet loss vis-à-vis treatment blood. At the same time, the elution of hydrophilic polymers from the lumen of the hollow fiber membrane is reduced.

The invention discloses an application of an Akt inhibitor in preparation of a drug for treating platelet number decrease related diseases. Experiments prove that Akt regulates apoptosis and activation of platelet by activating cyclic adenosine monophosphate dependent phosphodiesterase and phosphodiesterase medicated PKA (protein kinase A), the apoptotic and activated platelet exposes phosphatidylserine, so that the phosphatidylserine is swallowed by macrophages. Inhibition or gene knockout of Akt or Akt medicated platelet activation and apoptosis or blocking of phosphatidylserine ectropion can stop clearance of antibody-bound platelet. Research indicates that the Akt inhibitor can be used for an anti-platelet membrane glycoprotein Ib alpha antibody to induce the treatment process of platelet number change related diseases and inhibit decrease of the number of platelets in peripheral circulation blood, so that the Akt inhibitor has the potential of being developed into novel platelet protection drugs and novel drugs for treating thrombocytopenic diseases and has great scientific research and economic value.